Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.

Only left-leaning outlets are covering this.

How each outlet headlined it

• StockStory

  Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.
• CNBC center

  Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Investing.com Stocks center

  Why is Eli Lilly stock surging today?
• The Wall Street Journal right

  Eli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs. on.wsj.com/4clxdRn